Literature DB >> 22168653

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Scott Pearson, Richard Troughton, A Mark Richards.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22168653     DOI： 10.1056/NEJMc1112233

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.

Authors:  Kevin E Chan; Elazer R Edelman; Julia B Wenger; Ravi I Thadhani; Franklin W Maddux
Journal:  Circulation       Date:  2015-01-16       Impact factor: 29.690

Review 2.  Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy.

Authors:  Mark Walsh; Stephanie Fritz; Daniel Hake; Michael Son; Sarah Greve; Manar Jbara; Swetha Chitta; Braxton Fritz; Adam Miller; Mary K Bader; Jonathon McCollester; Sophia Binz; Alyson Liew-Spilger; Scott Thomas; Anton Crepinsek; Faisal Shariff; Victoria Ploplis; Francis J Castellino
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

3.  Routine coagulation test abnormalities caused by rivaroxaban: A case report.

Authors:  Zikai Song; Haidi Wu; Hongyan Cao; Shuo Yang; Minglong Tang; Ling Qin
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

4.  Clinical outcomes of solitary atrial flutter patients using anticoagulation therapy: a national cohort study.

Authors:  Yung-Lung Chen; Yu-Sheng Lin; Hui-Ting Wang; Wen-Hao Liu; Huang-Chung Chen; Mien-Cheng Chen
Journal:  Europace       Date:  2019-02-01       Impact factor: 5.214
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.